Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 7/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21823283 | 0.82 | KMT2A (0.46) | ERN1KMT2AMEN1NPSR1LMNA | |
| SCHEMBL21823281 | 0.82 | KMT2A (0.46) | ERN1KMT2AMEN1NPSR1LMNA | |
| SCHEMBL4374159 | 0.80 | ERN1 (0.66) | ERN1LMNAMAPTL3MBTL1PRKDC | |
| SCHEMBL31663469 | 0.80 | ERN1 (0.66) | ERN1LMNAMAPTL3MBTL1PRKDC | |
| SCHEMBL21823418 | 0.74 | FPR2 (0.46) | KMT2AMEN1NPSR1LMNAMAPT | |
| SCHEMBL6583922 | 0.74 | PDE4D (0.44) | KMT2APOLBMEN1LMNAPDE4A | |
| SCHEMBL636344 | 0.74 | SRC (0.52) | ERN1KMT2APOLBLMNAMAPT | |
| SCHEMBL16096941 | 0.74 | POLB (0.40) | ERN1KMT2APOLBMEN1MAPT | |
| SCHEMBL2743917 | 0.73 | ERN1 (0.57) | ERN1KMT2AMEN1LMNAMAPT | |
| SCHEMBL21823620 | 0.73 | ERN1 (0.57) | ERN1LMNAMAPTMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166177-B | Boron-containing PDE4 inhibitors | 辉瑞公司 | 2024-09-03 | — | — | CN | disclosed |
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3861001-A1 | BORON CONTAINING PDE4 INHIBITORS | Pfizer Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-113166177-A | Boron-containing PDE4 inhibitors | 辉瑞公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PFIZER INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PFIZER INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2020-04-09 | — | — | US | disclosed |
| WO-2020070651-A1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PDE4B, PDE4A, PDE3B | ERN1 3025/4885KMT2A 2476/4885POLB 1020/4885 |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | ERN1 3340/4885KMT2A 1626/4885POLB 1544/4885 |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | ERN1 3340/4885KMT2A 1626/4885POLB 1544/4885 |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | ERN1 3340/4885KMT2A 1626/4885POLB 1544/4885 |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PDE4A, PDE4B, PDE12 | ERN1 3590/4885KMT2A 2943/4885POLB 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.